BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Stemline Therapeutics, Inc. (STML) Announces Oral Presentation of SL-401, a Clinical-Stage Targeted Therapy, Demonstrating Notable Preclinical Activity in an Additional Indication, Chronic Myeloid Leukemia (CML), at the 15th International Conference on CML


9/25/2013 9:13:41 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK, Sept. 25, 2013 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that SL-401, which is entering pivotal clinical trials in blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML), has shown preclinical activity in an additional hematologic cancer indication, chronic myeloid leukemia (CML). Marina Konopleva, MD, PhD, Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, will present studies detailing SL-401's notable activity against CML primary blasts and cancer stem cells (CSCs) in animal models and in vitro at the European School of Hematology (ESH) International Chronic Myeloid Leukemia Foundation (ICMLF) 15th International Conference on CML – Biology and Therapy in Estoril, Portugal on September 26-29, 2013. SL-401 significantly reduced the growth of CML blasts, as well as CSCs, from patients with tyrosine kinase inhibitor (TKI)-resistant CML. In addition, the combination of SL-401 and the TKI, imatinib (Gleevec), had a significant synergistic effect on inhibiting the growth of primary CML cells from patients. SL-401 also prolonged the survival of mice inoculated with primary cells from a CML patient in blast crisis who was resistant to several TKIs.

Help employers find you! Check out all the jobs and post your resume.


Read at GlobeNewswire

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES